Yaron Meirow is an accomplished immunotherapy project manager at Gamida Cell Ltd., contributing to advanced cell therapy product development since March 2022. Notably, Yaron played a crucial role in the IND enabling study and phase 1 clinical trials for the cryopreserved allogeneic NK-cell non-Hodgkin lymphoma therapy, GDA-201, as well as in addressing post-approval commitments to the FDA for the hematopoietic stem-cell therapy Omisirge. Prior to this role, Yaron conducted Ph.D. studies at The Concern Foundation Laboratories at the Lautenberg Center for Immunology and Cancer Research, focusing on the pathological mechanisms of inflammatory bone loss, culminating in a dissertation related to abnormal inflammatory immune cells and chronic inflammation. Educational credentials include a Ph.D. in Immunology and an MS in Oncology and Cancer Biology from esteemed institutions, complemented by a BS in Biology from The Hebrew University of Jerusalem.
This person is not in any teams
This person is not in any offices